Cargando…

Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis

BACKGROUND: Observational comparative effectiveness studies in allergen immunotherapy (AIT) represent an important evidence source answering research questions that can be challenging to obtain from randomized controlled trials (RCTs), such as long‐term benefits of AIT, the effects on asthma prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Bona, Danilo, Paoletti, Giovanni, Chu, Derek K., Pepys, Jack, Macchia, Luigi, Heffler, Enrico, Canonica, Giorgio Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203181/
https://www.ncbi.nlm.nih.gov/pubmed/34141180
http://dx.doi.org/10.1002/clt2.12033
_version_ 1783708116139900928
author Di Bona, Danilo
Paoletti, Giovanni
Chu, Derek K.
Pepys, Jack
Macchia, Luigi
Heffler, Enrico
Canonica, Giorgio Walter
author_facet Di Bona, Danilo
Paoletti, Giovanni
Chu, Derek K.
Pepys, Jack
Macchia, Luigi
Heffler, Enrico
Canonica, Giorgio Walter
author_sort Di Bona, Danilo
collection PubMed
description BACKGROUND: Observational comparative effectiveness studies in allergen immunotherapy (AIT) represent an important evidence source answering research questions that can be challenging to obtain from randomized controlled trials (RCTs), such as long‐term benefits of AIT, the effects on asthma prevention and the onset of new allergen sensitizations. However, observational studies are prone to several sources of bias, which limit their reliability. The REal Life Evidence AssessmeNt Tool (RELEVANT) was recently developed to assist in quality appraisal of observational comparative research to enable identification of useful nonrandomized studies to be considered within guideline development. OBJECTIVE: To systematically appraise the quality of published observational comparative AIT studies using RELEVANT. METHODS: Observational studies comparing AIT to pharmacotherapy for respiratory allergies, assessing as outcome measures reduction of symptoms and/or medication use reduction, were retrieved by computerized bibliographic searches. According to RELEVANT, a failure to meet any one of primary items (background, design, measures, analysis, results, discussion/interpretation, and conflict of interest) represents a critical flaw, significantly undermining the validity of the study results. RESULTS: The 14 studies identified supported the benefit of AIT in real‐life, which persists after treatment discontinuation. However, none of them met all the 7 primary RELEVANT criteria. The main defects were reported in the design (28.6% of studies), measures and analysis (64.3% of studies), and results (78.6% of studies) items, due to selection bias and lack of methods for adjusting controls. Half of the studies did not report on conflict of interest. CONCLUSION: There is a need for more robust observational research in AIT. RELEVANT appears as an easy‐to‐use and sensitive tool for quality appraisal in AIT studies.
format Online
Article
Text
id pubmed-8203181
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82031812021-06-16 Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis Di Bona, Danilo Paoletti, Giovanni Chu, Derek K. Pepys, Jack Macchia, Luigi Heffler, Enrico Canonica, Giorgio Walter Clin Transl Allergy Research BACKGROUND: Observational comparative effectiveness studies in allergen immunotherapy (AIT) represent an important evidence source answering research questions that can be challenging to obtain from randomized controlled trials (RCTs), such as long‐term benefits of AIT, the effects on asthma prevention and the onset of new allergen sensitizations. However, observational studies are prone to several sources of bias, which limit their reliability. The REal Life Evidence AssessmeNt Tool (RELEVANT) was recently developed to assist in quality appraisal of observational comparative research to enable identification of useful nonrandomized studies to be considered within guideline development. OBJECTIVE: To systematically appraise the quality of published observational comparative AIT studies using RELEVANT. METHODS: Observational studies comparing AIT to pharmacotherapy for respiratory allergies, assessing as outcome measures reduction of symptoms and/or medication use reduction, were retrieved by computerized bibliographic searches. According to RELEVANT, a failure to meet any one of primary items (background, design, measures, analysis, results, discussion/interpretation, and conflict of interest) represents a critical flaw, significantly undermining the validity of the study results. RESULTS: The 14 studies identified supported the benefit of AIT in real‐life, which persists after treatment discontinuation. However, none of them met all the 7 primary RELEVANT criteria. The main defects were reported in the design (28.6% of studies), measures and analysis (64.3% of studies), and results (78.6% of studies) items, due to selection bias and lack of methods for adjusting controls. Half of the studies did not report on conflict of interest. CONCLUSION: There is a need for more robust observational research in AIT. RELEVANT appears as an easy‐to‐use and sensitive tool for quality appraisal in AIT studies. John Wiley and Sons Inc. 2021-06-14 /pmc/articles/PMC8203181/ /pubmed/34141180 http://dx.doi.org/10.1002/clt2.12033 Text en © 2021 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Di Bona, Danilo
Paoletti, Giovanni
Chu, Derek K.
Pepys, Jack
Macchia, Luigi
Heffler, Enrico
Canonica, Giorgio Walter
Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title_full Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title_fullStr Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title_full_unstemmed Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title_short Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis
title_sort allergen immunotherapy for respiratory allergy: quality appraisal of observational comparative effectiveness studies using the real life evidence assessment tool. an eaaci methodology committee analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203181/
https://www.ncbi.nlm.nih.gov/pubmed/34141180
http://dx.doi.org/10.1002/clt2.12033
work_keys_str_mv AT dibonadanilo allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT paolettigiovanni allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT chuderekk allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT pepysjack allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT macchialuigi allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT hefflerenrico allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis
AT canonicagiorgiowalter allergenimmunotherapyforrespiratoryallergyqualityappraisalofobservationalcomparativeeffectivenessstudiesusingthereallifeevidenceassessmenttoolaneaacimethodologycommitteeanalysis